Irsogladine maleate and rabeprazole in non-erosive reflux disease - a double-blind, placebo- controlled study
Not Applicable
- Conditions
- ERD
- Registration Number
- JPRN-UMIN000015731
- Lead Sponsor
- Tokai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded from the study if they were younger than 20 years, were allergic to rabeprazole or IM, had any level of esophagitis determined by gastrointestinal endoscopy, were pregnant, were taking anti-coagulant or anti-platelet agents, had a history of gastrointestinal malignancy, peptic ulcers, or gastrointestinal tract surgery, or if they had used any PPI therapy within four weeks of enrolling in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FSSG(frequency scale for the symptoms of GERD)
- Secondary Outcome Measures
Name Time Method SF-36(MOS Short-Form 36-Item Health Survey)